Cover Image
市場調查報告書

全球醫藥品受託製造廠商(CMO)市場

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

出版商 Frost & Sullivan 商品編碼 370709
出版日期 內容資訊 英文 302 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球醫藥品受託製造廠商(CMO)市場 Global Pharmaceutical Contract Manufacturing Organization (CMO) Market
出版日期: 2016年08月16日 內容資訊: 英文 302 Pages
簡介

本報告提供全球醫藥品受託製造廠商(CMO)市場相關調查,市場趨勢與成長市場區隔,市場機會與課題,競爭趨勢,以及全球各國的各國趨勢與關注企業彙整。

第1章 摘要整理

第2章 全球CMO市場環境

  • 大醫藥品CMO市場收益預測
  • API與中介CMO市場概要
  • FDF CMO市場概要
  • 醫藥品製造價值鏈中CMO所扮演的角色
  • 需求與市場允許
  • 經營模式的變化:虛擬製藥的崛起
  • 影響CMO選擇的特徵
  • 新的經營模式
  • 競爭能力
  • 全球CMO市場趨勢
  • 技術趨勢
  • 推動市場的要素
  • 阻礙市場的要素

第3章 競爭趨勢

  • 競爭環境
  • 產品、臨床服務、能力提供上CMO的擴大
  • 收益成長
  • CMO產業的不確定性製圖
  • 關注企業與其理由

第4章 主要合併,收購,聯盟

第5章 預測與趨勢

  • 評估
  • 預測
  • 收益預測
  • 各地區收益預測

第6章 各服務形式市場預測

第7章 全球API及中介CMO市場明細

第8章 全球FDF CMO市場明細

第9章 市場佔有率和競爭分析

第10章 美國市場

第11章 美國的API及中介CMO市場

第12章 美國的FDF CMO市場明細

第13章 美國的關注企業

第14章 西歐市場

第15章 西歐的API及中介CMO市場

第16章 西歐的FDF CMO市場明細

第17章 西歐各國趨勢

第18章 德國市場

第19章 英國市場

第20章 法國市場

第21章 義大利市場

第22章 西班牙市場

第23章 斯堪地那維亞各國市場

第24章 荷比盧三國市場

第25章 西歐的關注企業

第26章 亞太地區市場

第27章 亞太地區的API及中介CMO市場

第28章 亞太地區的FDF CMO市場明細

第29章 亞太地區各國趨勢

第30章 中國市場

第31章 印度市場

第32章 日本市場

第33章 最後

第34章 附錄

目錄
Product Code: P8D4-01-00-00-00

Emerging Business Models Drive Transformation

The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments-active pharmaceutical ingredients (APIs) and intermediates; and finished dose formulations (FDFs), further segmented by solid, liquid and semi-solid, and injectable doses-and to understand the value chain from clinical to commercial, and drug substrate to final drug product of the CMOs, biotech, and pharma companies. Additional goals are to analyze the dynamics catalyzing growth, profile organizations presenting significant opportunities, and outline industry consolidation trends that will continue shaping the market. The base year of analysis is 2015 and forecasts run from 2016 to 2020.

Key Questions This Study Will Answer

  • Is the pharmaceutical CMO market growing, how long will it continue to grow, and at what rate?
  • What are the fastest growing segments of the pharmaceutical CMO market?
  • What growth opportunities exist in the pharmaceutical CMO industry?
  • What are the key drivers and restraints affecting the growth of CMOs?
  • What are the key challenges the CMOs are likely to face in the near and long-term? How can CMOs strategize to overcome these hurdles?
  • In what ways is the pharmaceutical CMO industry likely to change to meet industry trends and dynamics?
  • Who are the game-changing companies and what are the disruptive technologies and business models? How do CMOs position their assets with pharma companies?

Table of Contents

1. EXECUTIVE SUMMARY

  • 1. Key Findings-Pharmaceutical CMO Market
  • 2. Key Findings-Pharmaceutical CMO Market (continued)
  • 3. Scope and Geographic Segmentation
  • 4. Market Segmentation
  • 5. Methodology
  • 6. Key Questions This Study Will Answer
  • 7. Measurements
  • 8. Measurements (continued)
  • 9. Global Manufacturing Footprint-Key CMO Companies
  • 10. Transformation of Industry Ecosystem
  • 11. Trends for the FDF CMO Market
  • 12. Trends for the API and Intermediates CMO Market
  • 13. Key Technology Trends-Preference for Disposable Technologies
  • 14. Key Technology Trends-Rising Demand of Lyophilization
  • 15. Key Investment Trends
  • 16. Game-changing Companies
  • 17. Customer Segment Revenue Contribution Analysis
  • 18. 8 Big Market Themes for Contract Manufacturing

2. GLOBAL CMO MARKET LANDSCAPE

  • 1. Total Pharmaceutical CMO Market Revenue Forecast
  • 2. Revenue Forecast Discussion
  • 3. API and Intermediates CMO Market Overview
  • 4. FDF CMO Market Overview
  • 5. FDF CMO Market Overview (continued)
  • 6. Role of CMOs in the Pharmaceutical Manufacturing Value Chain
  • 7. API and Intermediates and FDF Industry Ecosystem
  • 8. Demand and Market Acceptance of Customers' Products
  • 9. Changing Business Model-Rise in Virtual Pharma
  • 10. Virtual Pharma-Change Makers in Pharma and Biotech Outsourcing Ecosystem
  • 11. Key Characteristics Influencing CMO Selection
  • 12. New Business Models
  • 13. Comparative Capability Analysis of Key Participants in the Pharma/ Biotech Contract Outsourcing Market
  • 14. Global CMO Key Market Trends
  • 15. Global CMO Key Market Trends (continued)
  • 16. Key Technology Trends-Inclination towards Continuous Manufacturing
  • 17. Key Technology Trends-Prominence of Gamma Sterilization
  • 18. Key Technology Trends-Rising Acceptance of Process Analytical Technologies (PAT)
  • 19. Key Market Drivers
  • 20. Key Market Restraints

3. COMPETITIVE PLAYBOOK

  • 1. Snapshot of Competitive Landscape
  • 2. Snapshot of Competitive Landscape (continued)
  • 3. CMO Expansions in Products, Clinical Services, and Capacity Offerings
  • 4. CMO Expansions in Products, Clinical Services, and Capacity Offerings (continued)
  • 5. Differential Revenue Growth
  • 6. Uncertainty Matrix-Mapping of Key CMO Industry Uncertainties
  • 7. Possible Industry Overcapacity
  • 8. 10 Companies to Watch and Why

4. KEY MERGER, ACQUISITION, AND PARTNERSHIP AGREEMENTS OF THE CONTRACT MANUFACTURING MARKETS

  • 1. Key Mergers and Acquisitions
  • 2. Notable Mergers and Acquisitions-CMO Industry on a Consolidation Spree
  • 3. Notable Mergers & Acquisitions-CMO Industry on a Consolidation Spree (continued)
  • 4. Key Merger, Acquisition, and Partnership Agreements
  • 5. Key Merger, Acquisition, and Partnership Agreements (continued)
  • 6. Key Merger, Acquisition, and Partnership Agreements (continued)
  • 7. Key Merger, Acquisition, and Partnership Agreements (continued)
  • 8. Key Merger, Acquisition, and Partnership Agreements (continued)
  • 9. Key Merger, Acquisition, and Partnership Agreements (continued)
  • 10. Key Merger, Acquisition, and Partnership Agreements (continued)
  • 11. Key Merger, Acquisition, and Partnership Agreements (continued)
  • 12. Key Merger, Acquisition, and Partnership Agreements (continued)
  • 13. Key FDF CMO Segment Strategic Collaborations
  • 14. Key API and Intermediates Segment Strategic Collaborations

5. FORECAST AND TRENDS-TOTAL PHARMACEUTICAL CMO MARKET

  • 1. Measurements
  • 2. Measurements (continued)
  • 3. Forecast Assumptions
  • 4. Total Pharmaceutical CMO Market Revenue Forecast
  • 5. Revenue Forecast Discussion
  • 6. Revenue Forecast Discussion (continued)
  • 7. Total Pharmaceutical CMO Market Percent Revenue Forecast by Region
  • 8. Total Pharmaceutical CMO Market Revenue Forecast by Region

6. TOTAL PHARMACEUTICAL CMO MARKET FORECAST BY SERVICE TYPE

  • 1. Total Pharmaceutical CMO Market Percent Revenue Forecast by Service Type
  • 2. Total Pharmaceutical CMO Market Revenue Forecast by Service Type
  • 3. Revenue Forecast Discussion

7. GLOBAL API AND INTERMEDIATES CMO MARKET BREAKDOWN

  • 1. API and Intermediates CMO Market Overview
  • 2. Value Chain of Pharmaceutical Manufacturing
  • 3. Market Segmentation
  • 4. API and Intermediates CMO Market Revenue Forecast
  • 5. API and Intermediates CMO Market Percent Revenue Breakdown by Geographic Region
  • 6. API CMO Market Percent Revenue Breakdown by Synthesis Route
  • 7. API and Intermediates CMO Market Revenue Forecast by Synthesis Route
  • 8. API and Intermediates CMO Market Percent Revenue Breakdown by Customer Base
  • 9. API and Intermediates CMO Market Revenue Breakdown by Customer Base
  • 10. Revenue Forecast Discussion

8. GLOBAL FDF CMO MARKET BREAKDOWN

  • 1. Market Segmentation
  • 2. FDF CMO Market Percent Revenue Breakdown by Geographic Region
  • 3. FDF CMO Market Percent Revenue Forecast by Dosage Form
  • 4. FDF CMO Market Percent Revenue Breakdown by Patent Exclusivity Status
  • 5. FDF CMO Market Revenue Forecast
  • 6. FDF CMO Market Percent Revenue Forecast by Dosage Form
  • 7. FDF CMO Market Revenue Forecast by Dosage Form
  • 8. Revenue Forecast Discussion
  • 9. Revenue Forecast Discussion (continued)

9. MARKET SHARE AND COMPETITIVE ANALYSIS

  • 1. Global FDF CMO Market Share Analysis
  • 2. Global FDF CMO Market Share Analysis (continued)
  • 3. API and Intermediates CMO Market-Competitive Structure
  • 4. Key CMO Breakdown by APIs and FDFs
  • 5. Key CMO Breakdown by API and FDFs (continued)

10. UNITED STATES BREAKDOWN

  • 1. Market Overview
  • 2. Market Analysis
  • 3. Measurements
  • 4. US Pharmaceutical CMO Market Revenue Forecast
  • 5. US Pharmaceutical CMO Market Revenue Forecast by Service Type

11. US API AND INTERMEDIATES CMO MARKET

  • 1. US API and Intermediates CMO Market Revenue Forecast
  • 2. Revenue Forecast Discussion

12. US FDF CMO MARKET BREAKDOWN

  • 1. US FDF CMO Market Revenue Forecast
  • 2. Revenue Forecast Discussion
  • 3. US Solid Dose Formulations Segment Revenue Forecast
  • 4. US Solid Dose Formulations Segment Revenue Forecast Discussion
  • 5. US Liquid and Semi-solid Dose Formulations Segment Revenue Forecast
  • 6. US Liquid and Semi-solid Dose Formulations Segment Revenue Forecast Discussion
  • 7. US Injectable Dose Formulations Segment Revenue Forecast
  • 8. US Injectable Dose Formulations Segment Revenue Forecast Discussion
  • 9. Pricing Analysis
  • 10. PESTLE Analysis

13. US-KEY COMPANIES TO WATCH

  • 1. Patheon
  • 2. Patheon (continued)
  • 3. Patheon-Major Partnerships and Agreements
  • 4. Catalent
  • 5. Catalent (continued)
  • 6. Catalent-Major Partnerships and Agreements
  • 7. Baxter Biopharma Solutions
  • 8. Baxter Biopharma Solutions (continued)

14. WESTERN EUROPE BREAKDOWN

  • 1. Market Overview
  • 2. Market Analysis
  • 3. Measurements
  • 4. Western European Pharmaceutical CMO Market Revenue Forecast
  • 5. Western European Pharmaceutical CMO Market Revenue Forecast by Service Type
  • 6. Western European FDF CMO Market Revenue Forecast by Dosage Form
  • 7. Western Europe Revenue Forecast Discussion

15. WESTERN EUROPE API AND INTERMEDIATES CMO MARKET BREAKDOWN

  • 1. Western Europe API and Intermediates CMO Market Revenue Forecast
  • 2. Western Europe API and Intermediates CMO Market Revenue Forecast Discussion

16. WESTERN EUROPE FDF CMO MARKET BREAKDOWN

  • 1. Western Europe FDF CMO Market Revenue Forecast
  • 2. Solid Dose Formulations Segment Revenue Forecast
  • 3. Solid Dose Formulations Segment Revenue Forecast Discussion
  • 4. Liquid and Semi-solid Dose Formulations Segment Revenue Forecast
  • 5. Liquid and Semi-solid Dose Formulations Segment Revenue Forecast Discussion
  • 6. Injectable Dose Formulations Segment Revenue Forecast
  • 7. Injectable Dose Formulations Segment Revenue Forecast Discussion
  • 8. Pricing Analysis
  • 9. PESTLE Analysis

17. BREAKDOWN BY KEY WESTERN EUROPE COUNTRIES

  • 1. Market Segmentation for Western Europe Breakdown

18. GERMANY BREAKDOWN

  • 1. Germany FDF CMO Market Revenue Forecast
  • 2. Germany FDF CMO Market Revenue Forecast by Dosage Form
  • 3. Germany Solid Dose Formulations Segment Revenue Forecast
  • 4. Germany Liquid and Semi-solid Dose Formulations Segment Revenue Forecast
  • 5. Germany Injectable Dose Formulations Segment Revenue Forecast

19. UK BREAKDOWN

  • 1. UK FDF CMO Market Revenue Forecast
  • 2. UK FDF CMO Market Revenue Forecast by Dosage Form
  • 3. UK Solid Dose Formulations Segment Revenue Forecast
  • 4. UK Liquid and Semi-solid Dose Formulations Segment Revenue Forecast
  • 5. UK Injectable Dose Formulations Segment Revenue Forecast

20. FRANCE BREAKDOWN

  • 1. France FDF CMO Market Revenue Forecast
  • 2. France FDF CMO Market Revenue Forecast by Dosage Form
  • 3. France Solid Dose Formulations Segment Revenue Forecast
  • 4. France Liquid and Semi-solid Dose Formulations Segment Revenue Forecast
  • 5. France Injectable Dose Formulations Segment Revenue Forecast

21. ITALY BREAKDOWN

  • 1. Italy FDF CMO Market Revenue Forecast
  • 2. Italy FDF CMO Market Revenue Forecast by Dosage Form
  • 3. Italy Solid Dose Formulations Segment Revenue Forecast
  • 4. Italy Liquid and Semi-solid Dose Formulations Segment Revenue Forecast
  • 5. Italy Injectable Dose Formulations Segment Revenue Forecast

22. SPAIN BREAKDOWN

  • 1. Spain FDF CMO Market Revenue Forecast
  • 2. Spain FDF CMO Market Revenue Forecast by Dosage Form
  • 3. Spain Solid Dose Formulations Segment Revenue Forecast
  • 4. Spain Liquid and Semi-solid Dose Formulations Segment Revenue Forecast
  • 5. Spain Injectable Dose Formulations Segment Revenue Forecast

23. SCANDINAVIA BREAKDOWN

  • 1. Scandinavia FDF CMO Market Revenue Forecast
  • 2. Scandinavia FDF CMO Market Revenue Forecast by Dosage Form
  • 3. Scandinavia Solid Dose Formulations Segment Revenue Forecast
  • 4. Scandinavia Liquid and Semi-solid Dose Formulations Segment Revenue Forecast
  • 5. Scandinavia Injectable Dose Formulations Segment Revenue Forecast

24. BENELUX BREAKDOWN

  • 1. Benelux FDF CMO Market Revenue Forecast
  • 2. Benelux FDF CMO Market Revenue Forecast by Dosage Form
  • 3. Benelux Solid Dose Formulations Segment Revenue Forecast
  • 4. Benelux Liquid and Semi-solid Dose Formulations Segment Revenue Forecast
  • 5. Benelux Injectable Dose Formulations Segment Revenue Forecast

25. WESTERN EUROPE-KEY COMPANIES TO WATCH

  • 1. Aenova
  • 2. Aenova (continued)
  • 3. Aenova-Major Partnerships and Agreements
  • 4. Famar
  • 5. Famar (continued)
  • 6. Famar-Major Partnerships and Agreements
  • 7. Fareva
  • 8. Fareva (continued)
  • 9. Fareva-Major Partnerships and Agreements
  • 10. DTP Laboratories
  • 11. DPT Laboratories (continued)
  • 12. DPT Laboratories-Major Partnerships and Agreements
  • 13. Vetter Pharma
  • 14. Vetter Pharma (continued)
  • 15. Vetter Pharma-Major Partnerships and Agreements
  • 16. Consort Medical (Aesica/Bespak)
  • 17. Consort Medical
  • 18. Consort Medical-Major Partnerships and Agreements
  • 19. Recipharm
  • 20. Recipharm (continued)
  • 21. Recipharm-Major Partnerships and Agreements

26. APAC BREAKDOWN

  • 1. Market Overview
  • 2. Measurements
  • 3. APAC Pharmaceutical CMO Market Revenue Forecast
  • 4. APAC Pharmaceutical CMO Market Revenue Forecast by Service Type
  • 5. APAC Revenue Forecast Discussion

27. APAC API AND INTERMEDIATES CMO MARKET BREAKDOWN

  • 1. APAC API and Intermediates CMO Market Revenue Forecast
  • 2. APAC API and Intermediates CMO Market Revenue Forecast Discussion

28. APAC FDF CMO MARKET BREAKDOWN

  • 1. APAC FDF CMO Market Revenue Forecast
  • 2. APAC FDF CMO Market Percent Revenue Forecast by Dosage Form
  • 3. APAC FDF CMO Market Revenue Forecast by Dosage Form
  • 4. APAC FDF CMO Market Revenue Forecast Discussion
  • 5. Pricing Analysis
  • 6. PESTLE Analysis

29. BREAKDOWN BY KEY APAC COUNTRIES

  • 1. Market Segmentation for APAC Breakdown

30. CHINA BREAKDOWN

  • 1. Market Summary-China
  • 2. China Pharmaceutical CMO Market Revenue Forecast
  • 3. China Pharmaceutical CMO Market Revenue Forecast by Service Type
  • 4. China API and Intermediates CMO Market Revenue Forecast
  • 5. China FDF CMO Market Revenue Forecast
  • 6. China FDF CMO Market Revenue Forecast by Dosage Form
  • 7. China Solid Dose Formulations Segment Revenue Forecast
  • 8. China Liquid and Semi-solid Dose Formulations Segment Revenue Forecast
  • 9. China Injectable Dose Formulations Segment Revenue Forecast
  • 10. China Segment Discussion
  • 11. Huapont Pharm Co., Ltd
  • 12. Huapont Pharm Co., Ltd (continued)
  • 13. Huapont Pharm Co., Ltd-Major Partnerships and Agreements

31. INDIA BREAKDOWN

  • 1. Market Summary-India
  • 2. India Pharmaceutical CMO Market Revenue Forecast
  • 3. India Pharmaceutical CMO Market Revenue Forecast by Service Type
  • 4. India API and Intermediates CMO Market Revenue Forecast
  • 5. India FDF CMO Market Revenue Forecast
  • 6. India FDF CMO Market Revenue Forecast by Dosage Form
  • 7. India Solid Dose Formulations Segment Revenue Forecast
  • 8. India Liquid and Semi-solid Dose Formulations Segment Revenue Forecast
  • 9. India Injectable Dose Formulations Segment Revenue Forecast
  • 10. India Segment Discussion
  • 11. Dr. Reddy's Laboratories-Custom Pharma Services
  • 12. Dr. Reddy's Laboratories-Custom Pharma Services (continued)
  • 13. Dr. Reddy's Laboratories Custom Pharma Services-Major Partnerships and Agreements

32. JAPAN BREAKDOWN

  • 1. Market Summary-Japan
  • 2. Japan Pharmaceutical CMO Market Revenue Forecast
  • 3. Japan Pharmaceutical CMO Market Revenue Forecast by Service Type
  • 4. Japan API and Intermediates CMO Market Revenue Forecast
  • 5. Japan FDF CMO Market Revenue Forecast
  • 6. Japan FDF CMO Market Revenue Forecast by Dosage Form
  • 7. Japan Solid Dose Formulations Segment Revenue Forecast
  • 8. Japan Liquid and Semi-solid Dose Formulations Segment Revenue Forecast
  • 9. Japan Injectable Dose Formulations Segment Revenue Forecast
  • 10. Japan Segment Discussion
  • 11. Nipro Pharma Corporation
  • 12. Nipro Pharma Corporation-Custom Pharma Services
  • 13. Nipro Pharma Corporation-Major Partnerships and Agreements

33. THE LAST WORD-STRATEGIC CONSIDERATIONS FOR STAYING ON GROWTH TRAJECTORY

  • 1. Major Growth Opportunities
  • 2. Major Growth Opportunities (continued)
  • 3. Global API Outsourcing Scenario
  • 4. Growth Opportunities in API Contract Manufacturing
  • 5. Emerging CMO Business Model
  • 6. Risk Sharing Model-Achievable by Sharing the Following Resources
  • 7. Various Differentiation Strategies to Drive Long-term Profitability of CMOs
  • 8. Global Pharmaceutical CMO Market-Final Word
  • 9. Legal Disclaimer

34. APPENDIX

  • 1. Methodology
  • 2. List of Other Key Companies Included in This Research Service
Back to Top